Ricevi le ultime notizie sulle azioni Immix Biopharma con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di IMMX

Ultime notizie per

IMMIX BIOPHARMA INC

Immix Biopharma

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Immix Biopharma Inc

Press Releases

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Immix Biopharma Attends FDA CEO Forum in Washington DC

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

Immix Biopharma Announces Other Serious Diseases Strategy

Immix Biopharma to Present at the Stifel 2025 Healthcare Conference

Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang

Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

IMMX

ABVC BioPharma

Adicet Bio

Aligos Therapeutics

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

BeyondSpring

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Cibus

Clene

CervoMed

CEL-SCI

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Gain Therapeutics

MiNK Therapeutics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

MediciNova

NewAmsterdam Pharma Company N.V. - Warrant

NewAmsterdam Pharma Co

OS Therapies

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Repare Therapeutics

Sutro Biopharma

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

Comments

Immix Biopharma Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO